An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.

[1]  M. Stukova,et al.  Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. , 2015, Vaccine.

[2]  F. Mancini,et al.  Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination , 2015, The Journal of Immunology.

[3]  S. McVey,et al.  Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. , 2015, Vaccine.

[4]  P. Moris,et al.  Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination , 2015, Influenza and other respiratory viruses.

[5]  D. Bernstein,et al.  Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial , 2014, Open forum infectious diseases.

[6]  P. Chou,et al.  The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study , 2014, BMC Infectious Diseases.

[7]  W. Keitel,et al.  Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant , 2014, Open forum infectious diseases.

[8]  D. Vaughn,et al.  AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial , 2014, The Journal of infectious diseases.

[9]  R. Couch,et al.  Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older , 2014, BMC Infectious Diseases.

[10]  K. Subbarao,et al.  Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms , 2014, Expert review of vaccines.

[11]  Lucy A. Perrone,et al.  GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza , 2014, PloS one.

[12]  F. Di Virgilio,et al.  The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination , 2013, Proceedings of the National Academy of Sciences.

[13]  M. O'Hara,et al.  Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. , 2013, Vaccine.

[14]  Giuseppe Del Giudice,et al.  The history of MF59® adjuvant: a phoenix that arose from the ashes , 2013, Expert review of vaccines.

[15]  J. Beygo,et al.  Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects , 2012, Clinical and Vaccine Immunology.

[16]  S. Unal,et al.  A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. , 2012, Journal of preventive medicine and hygiene.

[17]  G. D. Cioppa,et al.  Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. , 2012, Vaccine.

[18]  T. Monath,et al.  Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. , 2012, Vaccine.

[19]  D. Vaughn,et al.  Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion , 2012, Expert review of vaccines.

[20]  D. Vaughn,et al.  Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03A-Adjuvanted Vaccination in Adults , 2011, The Journal of infectious diseases.

[21]  D. Vaughn,et al.  Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study , 2011, The Journal of infectious diseases.

[22]  R. Webby,et al.  PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. , 2011, Journal of pharmaceutical sciences.

[23]  P. Chomez,et al.  Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. , 2011, Vaccine.

[24]  G. Leroux-Roels,et al.  H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses , 2010, Journal of Clinical Immunology.

[25]  T. Vesikari,et al.  Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence , 2010, Pediatrics.

[26]  P. Shelat,et al.  Nanoemulsion: A pharmaceutical review , 2010 .

[27]  Shinn-Jang Hwang,et al.  Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. , 2009, Vaccine.

[28]  Volker Brauer,et al.  MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults , 2009, PloS one.

[29]  W. Keitel,et al.  Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. , 2008, The Journal of infectious diseases.

[30]  M. Zambon,et al.  Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. , 2008, Vaccine.

[31]  Rino Rappuoli,et al.  Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.

[32]  H. Ehrlich,et al.  A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. , 2008, The New England journal of medicine.

[33]  Mariagrazia Pizza,et al.  The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 , 2008, The Journal of Immunology.

[34]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[35]  A. Osterhaus,et al.  Pre- or post-pandemic influenza vaccine? , 2007, Vaccine.

[36]  Yu Wang,et al.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial , 2006, The Lancet.

[37]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[38]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[39]  A. Osterhaus,et al.  ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. , 1999, Vaccine.

[40]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[41]  J. Stockman.  A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture , 2010 .

[42]  Masahito Watanabe,et al.  IN MICE , 2009 .